Fixed Dose Combination (FDC) Therapy: A Comprehensive Review

Ms. Rehana Parveen[1*], Mr. Ranjeet Kumar Bhargav[2], Ms. Sakshi Minocha[3], Ms. Anjali Saxena[4], Ms. Khushboo Yadav[5], Mr. Mukesh Kumar Yadav[6]

[1, 3, 5, 6] Department of Pharmaceutics, Metro College of Health Sciences and Research, G.B. Nagar (U.P.)
[2]Department of Pharmaceutics, Spectrum Institute of Pharmaceutical Science and Research, G.B. Nagar (U.P.)
[4]Department of Pharmacology, Metro College of Health Sciences and Research, G.B. Nagar (U.P.)
Corresponding author: Ms. Rehana Parveen
Email: rehanaparveen22@gmail.com

Abstract

Fixed Dose Combination (FDC) therapy, the simultaneous administration of two or more active pharmaceutical ingredients in a single dosage form, has emerged as a valuable approach in modern medicine. This review article provides a comprehensive assessment of FDC therapy, covering its advantages, challenges, regulatory considerations, and impact on patients and healthcare systems. The review highlights the potential benefits of FDC therapy, including improved treatment outcomes, enhanced medication adherence, simplified dosing regimens, and cost-effectiveness. It also addresses concerns related to safety, efficacy, drug interactions, and regulatory frameworks associated with FDC therapy. By examining relevant literature, clinical studies, and real-world examples, this review aims to enhance the understanding of FDC therapy and its implications for healthcare professionals, regulators, and patients.

Keyword: Fixed-dose combination (FDC),Combination therapy,Multidrug therapy, Combination drugs, Drug interaction, Dose optimization, Combined drug delivery, Combination treatment, Fixed-ratio combination

Introduction:

Fixed Dose Combination (FDC) therapy refers to the practice of combining two or more active pharmaceutical ingredients (APIs) in fixed proportions within a single dosage form. This approach allows for the simultaneous administration of multiple drugs, offering several advantages over separate individual drug formulations. FDC therapy has gained prominence in various therapeutic areas, including cardiovascular diseases, HIV/AIDS, tuberculosis, diabetes, and hypertension.

The concept of FDC therapy has been present in medicine for centuries, although it has evolved significantly over time. Ancient medicinal practices, such as Ayurveda and traditional Chinese medicine, employed herbal formulations combining multiple ingredients to treat various ailments. However, the modern concept of FDC therapy emerged with the advent of synthetic pharmaceuticals and advancements in pharmaceutical technology.

The historical development of FDC therapy gained momentum in the mid-20th century when the combination of anti-tuberculosis drugs became a standard treatment approach. The rationale behind this approach was to enhance treatment efficacy, simplify medication regimens, and reduce the development of drug resistance. Since then, FDC therapy has expanded to encompass a wide range of therapeutic areas and has become a subject of extensive research and development.

The evolution of FDC therapy has been shaped by several factors. Advances in pharmaceutical manufacturing technologies, including tablet compression, coating, and formulation techniques, have enabled the production of stable and bioequivalent FDC formulations. Additionally, clinical evidence supporting the benefits of FDC therapy, such as improved treatment outcomes and increased patient adherence, has further contributed to its widespread adoption.

Furthermore, the growing recognition of the global burden of chronic diseases and the need for effective and convenient treatment options has fueled the development and utilization of FDC therapy. Governments and healthcare organizations have increasingly emphasized the importance of FDCs in public health programs, particularly in resource-limited settings where simplified treatment regimens can enhance accessibility and compliance.

In conclusion, FDC therapy involves the simultaneous administration of multiple active pharmaceutical ingredients in fixed proportions. It has a rich historical background, dating back to ancient medicinal practices, and has evolved to become a prominent approach in modern medicine [1]. The subsequent sections of this review article will delve deeper into the benefits, challenges, regulatory considerations, and impact of FDC therapy on patients, healthcare systems, and society as a whole.

Advantages of FDC Therapy:

- **Enhanced treatment outcomes and synergistic effects:**
  FDC therapy can offer enhanced treatment outcomes by combining drugs that target different aspects of a disease or work through complementary mechanisms. The synergistic effects of combining multiple drugs in a fixed dose can lead to improved efficacy and better control of the disease. For example, in the management of hypertension, a combination of antihypertensive agents in an FDC can provide more effective blood pressure control compared to monotherapy.
- **Improved medication adherence and patient convenience:**
  FDC therapy can simplify medication regimens by reducing the number of pills patients need to take each day. This streamlined approach to dosing enhances patient convenience and reduces the complexity of medication schedules. As a result, FDCs can promote better adherence to the prescribed treatment, as patients are more likely to comply with a simplified regimen compared to taking multiple individual medications. Improved adherence, in turn, can lead to better disease management and outcomes.
- **Streamlined dosing and reduced pill burden:**
  FDC therapy reduces the pill burden for patients who require multiple medications for their treatment. Instead of taking multiple individual tablets or capsules, patients can benefit from a single FDC tablet or capsule that contains the necessary combination of drugs. This not only simplifies the dosing process but also reduces the potential for

errors in medication administration. Streamlined dosing can be particularly beneficial for elderly patients or those with cognitive impairments who may find it challenging to manage complex medication regimens.

- **Potential cost savings and resource utilization:**
  FDC therapy has the potential to contribute to cost savings in healthcare systems. By combining multiple drugs into a single formulation, FDCs can reduce the overall cost of medication production, packaging, and distribution. Additionally, FDC therapy can help optimize resource utilization by reducing the number of hospital visits, healthcare professional consultations, and laboratory tests associated with managing multiple individual medications. The cost-effectiveness of FDC therapy can be especially relevant in low-resource settings and for chronic diseases requiring long-term treatment [2].

Challenges and Concerns:

- **Safety considerations and adverse effects:**
  One of the primary concerns with FDC therapy is ensuring the safety of patients. Combining multiple drugs in a fixed dose increases the potential for drug interactions, which can lead to adverse effects or decreased therapeutic efficacy. The safety profile of each individual drug must be thoroughly evaluated, taking into account potential interactions and cumulative side effects. Monitoring for adverse reactions and long-term safety data collection are essential to ensure patient safety with FDC therapy.
- **Efficacy assessment and clinical trial design:**
  Determining the efficacy of FDC therapy can be challenging due to the complexity of assessing the combined effects of multiple drugs. Clinical trial design for FDCs requires careful consideration of appropriate study endpoints, patient selection criteria, and statistical analysis methods. Additionally, the availability of comparative data from trials with individual drugs versus FDCs can be limited, making it difficult to evaluate the added benefit of the combination therapy.
- **Drug interactions and pharmacokinetic considerations:**
  FDC therapy introduces the potential for drug-drug interactions, where the pharmacokinetics and pharmacodynamics of the combined drugs may be altered. Understanding the interaction potential and the resulting impact on drug levels, metabolism, and therapeutic effects is crucial. Pharmacokinetic studies should be conducted to evaluate the compatibility of drugs within an FDC and ensure that the intended therapeutic concentrations are achieved without compromising safety.

"Overall, the advantages of FDC therapy include enhanced treatment outcomes through synergistic effects, improved medication adherence and patient convenience, streamlined dosing regimens, and potential cost savings and resource utilization. These benefits make FDC therapy an attractive option in various therapeutic areas, offering patients and healthcare systems a more efficient and effective approach to managing complex diseases".

FDC therapy is subject to specific regulatory requirements and approval processes. Regulators must assess the safety, efficacy, and quality of FDCs through rigorous evaluation. Harmonization of regulatory frameworks across countries is essential to ensure consistent standards for FDC approvals. Challenges may arise in defining appropriate bioequivalence criteria, determining the therapeutic rationale for

combining drugs, and establishing guidelines for post-marketing surveillance to monitor the safety and effectiveness of FDCs.

Addressing these challenges requires collaboration among regulators, healthcare professionals, and pharmaceutical companies.Robust pharmacovigilance systems, post-marketing surveillance, and ongoing monitoring of FDC therapy are crucial to detect and manage any safety concerns that may arise. Additionally, continued research and development efforts are needed to optimize clinical trial designs and methodologies for evaluating the efficacy of FDCs, as well as to enhance understanding of drug interactions and pharmacokinetic considerations specific to FDC therapy.

By addressing these challenges and concerns, the development and appropriate use of FDC therapy can be guided by evidence-based practices, ensuring patient safety, and maximizing the benefits of combination therapies.[3-5]

Perspectives of Stakeholders:

Healthcare professionals: Attitudes and experiences:

Healthcare professionals play a crucial role in the prescription, administration, and monitoring of FDC therapy. Their perspectives are shaped by their clinical experiences, understanding of the scientific evidence, and interactions with patients. Some healthcare professionals may view FDC therapy positively, appreciating the convenience, improved adherence, and potential for better treatment outcomes. Others may express concerns regarding safety, drug interactions, and the need for individualized treatment approaches. It is essential to understand and address the perspectives of healthcare professionals to ensure effective implementation and utilization of FDC therapy.

Regulatory authorities: Evaluating FDC therapy:

Regulatory authorities are responsible for assessing the safety, efficacy, and quality of FDCs before granting approvals. Their perspectives are shaped by scientific evidence, clinical trial data, and considerations of public health. Regulatory authorities evaluate FDC therapy based on rigorous standards, ensuring that the benefits outweigh the risks. They play a crucial role in establishing guidelines, defining approval processes, and monitoring the post-marketing safety and effectiveness of FDCs. Understanding the perspectives and criteria used by regulatory authorities is important for pharmaceutical companies developing FDCs and for healthcare professionals prescribing them[6].

Patients: Perceptions and acceptance:

Patient perspectives on FDC therapy are essential, as they are the end-users of these medications. Patients may appreciate the convenience of FDCs, particularly if they have a high pill burden or find it challenging to adhere to complex medication regimens. Patient acceptance may also depend on factors such as cost, availability, and trust in healthcare professionals' recommendations. It is important to involve patients in shared decision-making, providing them with information on the benefits, potential risks, and alternatives to FDC therapy. Understanding patient perceptions and addressing their concerns can contribute to improved treatment adherence and outcomes.

Civil society and advocacy groups: Balancing benefits and risks:

Civil society organizations and advocacy groups often play a role in influencing healthcare policies and decisions. Their perspectives may encompass a wide range of considerations, including patient safety, accessibility, affordability, and ethical concerns. These groups may advocate for increased awareness and education on FDC therapy, emphasize the importance of patient rights and autonomy, and raise awareness of potential risks and challenges[7]. Engaging with civil society and advocacy groups can foster a balanced discussion on the benefits and risks of FDC therapy and help shape policies and guidelines that prioritize patient well-being.

Understanding the perspectives of different stakeholders is crucial in developing and implementing FDC therapy effectively. Collaboration between healthcare professionals, regulatory authorities, patients, and civil society groups is necessary to ensure a holistic approach that addresses concerns, maximizes benefits, and promotes patient-centred care.

Case Studies and Examples:

1. **HIV/AIDS Treatment:** One of the most notable success stories of FDC therapy is in the treatment of HIV/AIDS. Antiretroviral therapy (ART) combines multiple drugs in FDC formulations, simplifying treatment regimens and improving medication adherence. FDCs have been instrumental in expanding access to HIV treatment globally, particularly in resource-limited settings. The World Health Organization (WHO) recommends FDC-based ART as the preferred treatment approach due to its effectiveness, convenience, and cost-effectiveness[8].
2. **Tuberculosis (TB) Treatment:** FDC therapy has also been successful in the management of tuberculosis. FDCs combining multiple anti-tuberculosis drugs have proven to be effective in improving treatment outcomes and reducing the development of drug resistance. The use of FDCs in TB treatment has simplified dosing regimens, increased treatment adherence, and reduced pill burden, contributing to better patient outcomes and public health efforts to control the spread of TB.
3. **Hypertension Management:** FDC therapy has shown promise in the management of hypertension. Combination FDCs that include different classes of antihypertensive drugs, such as angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, and diuretics, have demonstrated improved blood pressure control compared to monotherapy. These FDCs simplify dosing regimens and enhance patient adherence, leading to better management of hypertension and reduced cardiovascular risks.
4. **Diabetes Treatment:** FDC therapy has been explored in diabetes management to combine multiple drugs targeting different aspects of the disease. For example, FDCs combining metformin with other antidiabetic agents, such as sulfonylureas or dipeptidyl peptidase-4 (DPP-4) inhibitors, offer simplified dosing regimens and improved glycaemic control. FDCs in diabetes treatment can potentially reduce pill burden, enhance patient adherence, and optimize therapeutic outcomes.





Lessons learned from real-world applications:

- **Tailoring FDC therapy to patient needs:** Successful implementation of FDC therapy requires considering patient characteristics, treatment goals, and preferences. The selection of drugs and dosages in an FDC should be based on evidence, individual patient profiles, and the therapeutic rationale for combining specific agents. Taking into account patient diversity and ensuring personalized treatment approaches can optimize the effectiveness and acceptance of FDC therapy [9].
- **Monitoring for drug interactions and adverse effects:** Vigilant monitoring for potential drug interactions and adverse effects is essential in FDC therapy. Regular pharmacovigilance and post-marketing surveillance are crucial to identify and address any safety concerns. Real-world data collection and analysis can provide insights into the safety and effectiveness of FDCs in diverse patient populations and help refine treatment guidelines and recommendations.
- **Regulatory oversight and harmonization:** Effective regulatory oversight, including robust approval processes and post-marketing surveillance, is critical to ensuring the quality, safety, and efficacy of FDC therapy. Harmonization of regulatory standards and collaboration among regulatory authorities can facilitate efficient evaluation and

approval of FDCs, enabling timely access to innovative combination therapies while maintaining patient safety.

- **Patient education and shared decision-making:** Patient education plays a vital role in promoting awareness and understanding of FDC therapy. Empowering patients with information on the benefits, potential risks, and alternatives allows for shared decision-making between patients and healthcare professionals. Patient-centred communication and support can enhance patient acceptance, adherence, and treatment outcomes.

These case studies and lessons learned highlight the successful implementation of FDC therapy in various disease areas and provide insights into optimizing treatment regimens, ensuring patient safety, and maximizing therapeutic benefits in real-world settings.

Future Directions and Recommendations [10-15]:

1. **Research priorities and areas for further investigation:**

- **Long-term safety and effectiveness:** Continued research are needed to evaluate the long-term safety and effectiveness of FDC therapy, including the assessment of potential cumulative effects and late-onset adverse events.
- **Optimal drug combinations and dosages:** Further investigation is warranted to identify the most effective combinations of drugs and dosages in FDC formulations, considering factors such as pharmacokinetics, synergistic effects, and individual patient characteristics.
- **Real-world effectiveness:** Real-world studies and comparative effectiveness research can provide valuable insights into the effectiveness of FDC therapy in diverse patient populations and healthcare settings, helping to bridge the gap between clinical trials and real-world outcomes.
- **Paediatric and geriatric populations:** Research focused on FDC therapy in pediatric and geriatric populations is necessary to understand the safety, efficacy, and dosage requirements specific to these age groups.

2. **Policy considerations and regulatory frameworks:**

- **Harmonization of regulatory standards:** Collaboration among regulatory authorities globally can facilitate harmonization of approval processes, bioequivalence criteria, and safety monitoring requirements for FDC therapy. This can streamline the development, evaluation, and approval of FDCs while ensuring patient safety and quality.
- Clear guidelines for FDC development: Regulatory agencies should provide clear guidelines on the development, evaluation, and post-marketing surveillance of FDCs. These guidelines should address issues such as drug selection, dosage determination, bioequivalence criteria, and potential drug interactions.
- **Flexible regulatory pathways:** Regulatory agencies could consider implementing flexible regulatory pathways for FDCs, taking into account the unique characteristics and therapeutic rationale of combination therapies. This can encourage innovation in FDC development and expedite patient access to beneficial combination therapies.

3. **Patient education and awareness initiatives:**

- **Enhanced patient-centred communication:** Healthcare professionals should engage in effective communication with patients, providing clear and understandable

information about the benefits, potential risks, and appropriate use of FDC therapy. This can empower patients to make informed decisions and actively participate in their treatment. [16]

- **Patient education materials:** Development of patient education materials, such as brochures, videos, and online resources, can help increase awareness and understanding of FDC therapy among patients. These materials should be accessible, culturally appropriate, and available in multiple languages.
- **Patient support groups and counselling:** Establishing patient support groups and offering counsellingservices can provide a platform for patients to share experiences, address concerns, and receive personalized guidance on FDC therapy. These initiatives can promote patient engagement and adherence.

  By prioritizing research, establishing appropriate policy frameworks, and implementing patient education initiatives, the future of FDC therapy can be shaped in a way that maximizes its benefits and ensures the well-being of patients. These recommendations can contribute to the development and utilization of safe, effective, and patient-centred FDC therapies across various disease areas [17].

Conclusion:

Fixed Dose Combination (FDC) therapy offers several advantages, including enhanced treatment outcomes, improved medication adherence, streamlined dosing, and potential cost savings. FDCs have been successfully implemented in various disease areas such as HIV/AIDS, tuberculosis, hypertension, and diabetes, leading to improved patient outcomes and increased accessibility to treatment. The use of FDCs has simplified medication regimens, reduced pill burden, and enhanced patient convenience [18-22].

However, there are challenges and concerns associated with FDC therapy, including safety considerations, efficacy assessment, drug interactions, and regulatory frameworks. Addressing these challenges requires collaboration among healthcare professionals, regulatory authorities, and stakeholders. It is essential to ensure the safety of FDC therapy by monitoring for adverse effects, evaluating drug interactions, and conducting long-term safety studies.

The perspectives of stakeholders, including healthcare professionals, regulatory authorities, patients, and civil society, are crucial in shaping the implementation and acceptance of FDC therapy. Healthcare professionals play a key role in prescribing and monitoring FDC therapy, while regulatory authorities assess its safety and efficacy. Patient perspectives and education initiatives are vital for promoting acceptance and adherence to FDC therapy, and civil society and advocacy groups can help balance the benefits and risks [23].

Recommendations for the future include prioritizing research on long-term safety and effectiveness, optimizing drug combinations, and studying FDC therapy in specific populations. Policy considerations should focus on harmonizing regulatory standards, providing clear guidelines, and implementing flexible regulatory pathways for FDCs. Patient education and awareness initiatives should be enhanced through patient-centered communication, educational materials, and support groups [24-25].

"FDC therapy has the potential to significantly impact the general public, civil society, and patients by improving treatment outcomes, enhancing medication adherence, and reducing healthcare burden. By addressing challenges, conducting further research, implementing appropriate policies, and promoting patient education, FDC therapy can be effectively utilized to improve healthcare outcomes and meet the needs of diverse patient populations".

Reference:

1. Aditya Kalra, India bans 328 combination drugs in setback for pharma companies, Reuters, 13 September 2018, https://in.reuters.com/ article/us-india-health-drugs/india-bans-328-combination-drugs-insetback-for-pharma-companies-idINKCN1LT155 (accessed September 17, 2018).
2. Historically, branded drug is generally a product of innovator company who has undertaken expensive clinical trials or its authorisation holder who markets the drug under a brand name, fixing the price inclusive of all R&D costs, royalty payments and marketing costs. In 1980s, with a view to bring down price of medicines, the US government started issuing manufacturing and sale licenses for innovator drugs post-expiry of the patent protection period to other companies too, depending on the less expensive bioequivalence studies. Such drugs, marketed with their chemical names are called generic drugs and come at a significantly lower cost. When the same concept came to India, established pharma companies selling branded drugs also started their own versions of generics as branded generics, pricing their products in between the ranges of branded and generic drugs. This resulted in a complex and confusing scenario for the generic drug market in India, in which the cost saving benefits of generics could not be ensured.
3. Times News Network, 'SC stays ban on manufacture & sale of Saridon, 2 other drugs ', The Time s of India, 18 September 2018, https://timesofindia.indiatimes.com/india/sc-stays-drug-ban-allowsmanufacture-sale-of-3-fdcs/articleshow/65849551.cms (accessed September 20, 2018).
4. Blomberg Bjorn, Spinaci Sergio, Fouries Bernard and Laing Richard, The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis, Bulletin of the World Health Organisation, Decoding the Ban on Irrational Fixed-Dose Combination Drugs in India 30 ORF OCCASIONAL PAPER # 177 • NOVEMBER 2018 World Health Organization, 2001, http://www.who.int/bulletin/ archives/79(1)61.pdf (accessed September 18, 2018).
5. Roderick Peter, Mahajan Rishikesh, McGettigan Patricia and Pollock Allyson M, India should introduce a new Drugs Act, 18 January 2014, The Lancet, https://www.thelancet.com/journals/lancet/article/ PIIS0140-6736(14)60059-3/fulltext (accessed September 17, 2018).
6. Yogendra Kumar Gupta and Suganthi S Ramachandran, Fixed dose drug combinations: Issues and challenges in India, Indian Journal of Pharmacology, Jul-Aug 2016, http://www.ijp online.com/article.asp? issn=0253-7613; year=2016;volume=48; issue=4; spage=347; epage=349;aulast=Gupta (accessed September 22, 2018).

7. Roderick Peter, Mahajan Rishikesh, McGettigan Patricia and Pollock Allyson M, India should introduce a new Drugs Act, 18 January 2014, The Lancet, https://www.thelancet.com/journals/lancet/article/ PIIS0140-6736(14)60059-3/fulltext (accessed September 17, 2018).
8. 59th Report on the Functioning of the Central Drugs Standard Control Organisation (CDSCO), Department-Related Standing Committee on Health and Family Welfare, New Delhi, Parliament of India, 2012, http://164.100.47.5/newcommittee/reports/EnglishCommittees/Com mittee%20on%20Health%20and%20Family%20Welfare/59.pdf (accessed September 20, 2018).
9. Report of Expert Committee on 'Evaluation of Cases of Fixed Dose Combinations (FDCs) considered as Irrational and where Showcause Notices were Issued to the Applicants for submitting their Replies', 10 Februar y 2016, http://www. cds co.ni c .in/writereaddata/ fdcreport10_2_2016.pdf (accessed September 16, 2018).
10. Model List of Essential Medicines, March 2017, World Health Organisation, http://www.who.int/medicines/publications/ essentialmedicines/20th_EML2017.pdf?ua=1 (accessed September 16, 2018).
11. National List of Essential Medicines 2015, CDSCO, http://cdsco.nic.in/ WriteReadData/NLEM-2015/NLEM, %202015.pdf (accessed September 16, 2018). Decoding the Ban on Irrational Fixed-Dose Combination Drugs in India ORF OCCASIONAL PAPER # 177 • NOVEMBER 2018 31.
12. Revikumar KG and Veena R, Fixed dose combinations in Indian medicine market a SWOT analysis, MOJ Bioequivalence and Bioavailability, 20 December2017, https://medcraveonline.com/ MOJBB/MOJBB-04-00071.php (accessed September 24, 2018).
13. McGettiganPatrica, Roderick Peter, Mhajan Rishikesh, Kadam Abhay and Pollock Allyson M, Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing NonSteroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or P s y c h o t r o p i c D r u g s , P l o S M e d i c i n e , M a y 2 0 1 5 , https://www.ncbi.nlm.nih.gov/pubmed/25965416 (accessed September 20, 2018).
14. McGettiganPatrica, Roderick Peter, Kadam Abhay and Pollock Allyson, Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India, British Journal of Clinical Pharmacology, 4 February 2018, https://bpspubs.onlinelibrary. wiley.com/doi/abs/10.1111/bcp.13503 (accessed September 18, 2018).
15. Londe SP, Basavanagowda GM, Gowraw NS, Roopashree PM and Baishnad S, Study of Prescibing Pattern of Fixed Dose Combinations in the Medicine Department of a South Indian Tertiary Care Teaching Hospital, International Journal of Pharmaceutical Research Scholars, 2015, https://ijprs.com/wp-content/uploads/2018/09/IJPRS-V4-I1-00031.pdf (accessed October 1, 2018).
16. Somesh P Rayasam ,Sujata S Dudhgaonkar , Ganesh N Dakhale, Rohan C Hire, Prashant S Deshmukh and Nilesh N Gaikwad, The irrational fixed dose combinations in the Indian drug market: an evaluation of prescribing pattern using WHO guidelines, International Journal of Basic & Clinical Pharmacology, June 2013,

http://www.ijbcp.com/ index.php/ ijbcp/article/view/1298/1158 (accessed September 19, 2018).

17. Roderick Peter, Mahajan Rishikesh, McGettigan Patricia and Pollock Allyson M, India should introduce a new Drugs Act, 18 January 2014, The Lancet, https://www.thelancet.com/journals/lancet/article/ PIIS0140-6736(14)60059-3/fulltext (accessed September 17, 2018). Decoding the Ban on Irrational Fixed-Dose Combination Drugs in India 32 ORF OCCASIONAL PAPER # 177 • NOVEMBER 2018 20. Shyam B Verma, Sales, Status, prescriptions and regulatory problems with topical steroids in India", Indian Journal of Dermatology, Venerology and Leprology, May2014,http://www.ijdvl.com/article.asp?issn=03786323;year=2014;volume=80;issue=3;spage=201;epage=203;aulast= Verma(accessed October 9, 2018).
18. CDSCO. Policy Guidelines for the Approval of Fixed Dose Combinations (FDCs) in India; 2013. Available from: http://www. mohfw.nic.in/WriteReadData/l892s/6404452866Kokate%20 Report.pdf. [Last accessed on 2016 Jun 18].
19. CDSCO. Report of Expert Committee on Fixed Dose Combinations (FDCs) Licensed by SLAs for Manufacture without Approval of DCG (I), Applications of Which Received by CDSCO; 2015. Available from: http://www.cdsco.nic.in/writereaddata/ fdcexpert%2019.1.2016.pdf. [Last accessed on 2016 Jun 18].
20. CDSCO. Department-Related Parliamentary Standing Committee on Health and Family Welfare Fifty-Ninth Report on the Functioning of the Central Drugs Standard Control Organization (CDSCO); 2012. Available from: http://www. 164.100.47.5/ new committee/reports/English committees/committee%20 on%20health%20and%20family%20welfare/59.pdf. [Last accessed on 2016 Jun 18].
21. CDSCO. Letter Dated 15.01.2013 on Approval of Safety and Efficacy of Fixed Dose Combinations Permitted for Manufacture of Sale in the Country without Due Approval from DCGI; 2013. Available from: http://www.cdsco.nic.in/writereaddata/ Approval_of_the_safety_and_efficacy_of_FDC.pdf. [Last accessed on 2016 Jun 18].
22. CDSCO. Report of Expert Committee on Evaluation of Cases of Fixed Dose Combinations (FDCs) Considered as Irrational and Where Show cause Notices were Issued to the Applicants to Submit Their Replies; 2016. Available from: http://www.cdsco. nic.in/writereaddata/fdcreport10_2_2016.pdf. [Last accessed on 2016 Jun 18].
23. CDSCO. Prohibition of Fixed Dose Combination Drugs for Human Use Under Section 26A of Drugs and Cosmetics Act, 1940; 2016. Available from: http://www.cdsco.nic.in/writereaddata/ SKM_12-03-2016.pdf. [Last accessed on 2016 Jun 18].
24. Raghavan P. ET Bureau (March 30, 2016). Delhi High Court Refuses to Vacate Stay on Drug Ban; 2016.Availablefrom:http://www.articles.economictimes.indiatimes.com/2016-03-29/news/71900265_1_drug- controller-general-Delhi-high-court-central-drug-regulator. [Last accessed on 2016 Jun 18].
25. CDSCO. Notice Dated (June 17, 2015). Examination of Safety and Efficacy of FDCs Licensed for Manufacture for Sale in the Country without Due Approval from Office of DCGI; 2015. Available from: http://www.cdsco.nic.in/writereaddata/notice%20 letter17_6_2016_2016.pdf. [Last accessed on 2016 Jun 18].